Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ID Biomedical Corp.

Division of GlaxoSmithKline PLC
www.idbiomedical.com

Latest From ID Biomedical Corp.

Keeping Track: Seqirus Pandemic Flu Vaccine Approved; Trevena Resubmits Oliceridine

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Drug Review

Product Approvals In Brief: Xalkori Gets Full Approval, H5N1 Flu Vaccine Approved

Pfizer gains full approval for its lung cancer treatment Xalkori, following accelerated approval in 2011; also updates on ID Biomedical’s adjuvanted H5N1 flu vaccine; a new indication for Bayer/Onyx’s cancer treatment Nexavar; a new formulation for Merck’s antifungal Noxafil; and BTG’s new varicose vein product Varithena.

BioPharmaceutical United States

GSK’s Quad Flu Vaccine Clears FDA; B-Strain Protection Gap Could Drive Adoption

About one-third of the influenza B viruses tested this year are from the strain not included in this season’s trivalent vaccine; GlaxoSmithKline’s Fluarix is the second approved seasonal flu vaccine to protect against four virus strains, and by next season half of the U.S. manufacturers could be offering a broader spectrum product.

BioPharmaceutical United States

Flu Vaccine Production Down Slightly This Season; Strains Get Overhaul

FDA encourages people to get vaccinations since two of the three virus strains in this season’s flu vaccines differ from last season’s; several manufacturers plan to distribute slightly fewer doses in 2012-2013 than in the prior year.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Anthony F Holler, MD, CEO
    Kevin A Carlson, VP, Fin. & Admin. & CFO
    John Trizzino, SVP, Bus. Dev.
    George Lowell, CSO
    David Burt, VP, Research
  • Contact Info
  • ID Biomedical Corp.
    Phone: (604) 431-9314
    1510-800 West Pender St.
    Vancouver, V6C 2V6
    Canada
UsernamePublicRestriction

Register